Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: A pharmacokinetic justification

Current Medical Research and Opinion

Volumn 28, Issue 2, 2012, Pages 195-201

  Clemens, Andreas ^a   Haertter, Sebastian ^a   Friedman, Jeffrey ^b   Brueckmann, Martina ^a   Stangier, Joachim ^a   Van Ryn, Joanne ^a   Lehr, Thorsten ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Atrial fibrillation; Dabigatran; Pharmacokinetic modelling; Simulation

Indexed keywords

DABIGATRAN; ENOXAPARIN;

AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIMULATION; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; THROMBIN;

EID: 84856435683     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.654109     Document Type: Article

References (20)

1. Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am 2008;92:17-40,ix (Pubitemid 350182405)
2. Lip GY. The prothrombotic state in atrial fibrillation: new insights, more questions, and clear answers needed. Am Heart J 2000;140:348-50
3. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67 (Pubitemid 351650486)
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
5. U.S. Food and Drug Administration-Pradaxa Prescribing Information. Nov 2011. Available at: http://www.pradaxa.com/[Last accessed 30 November 2011]
6. European Medicines Agency. Pradaxa. Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en GB/document-library/EPAR-Product- Information/human/000829/WC500041059.pdf [Last accessed 24 August 2011]
7. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet 2009;48:1-22
8. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9:2168-75
9. Dansirikul C, Lehr T, Liesenfeld KH, et al. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopedic surgery. Thromb Haemost 2012 In press
10. Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 3:103-11 (Pubitemid 41647122)
11. Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59 (Pubitemid 350260888)
12. Boehringer Ingelheim. Advisory Committee Briefing Document. Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf [Last accessed 24 August 2011]
13. Wittkowsky A. Warfarin. In: Murphy JE Clinical pharmacokinetics. Baltimore: American Society of Health-System Pharmacists, 2008:345-68
14. U.S. Food and Drug Administration-FDA Briefing Information, Dabigatran Etexilate Mesylate Capsules, for the September 20, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Oct 19th 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf [Last accessed 24 August 2011]
15. Lehr T, Haertter S, Liesenfeld KH, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2011;Sep 28 [Epub ahead of print] doi:10.1177/0091270011417716
16. Ahrens I, Lip GY, Peter K. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation? Thromb Haemost 2011;105:574-78
17. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
18. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
19. Hedner T, Himmelmann A. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group. J Hypertens 1999;17:129-36 (Pubitemid 29086198)
20. Hori M, Connolly SJ, Ezekowitz MD, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation. Circ J 2011;75:800-05